{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:24:49Z","timestamp":1787019889106,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T00:00:00Z","timestamp":1111622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2005,3,24]],"date-time":"2005-03-24T00:00:00Z","timestamp":1111622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The objective was to improve understanding of adverse events occurring with celecoxib in the treatment of osteoarthritis and rheumatoid arthritis. Data were extracted from company clinical trial reports of randomised trials of celecoxib in osteoarthritis or rheumatoid arthritis lasting 2 weeks or more. Outcomes were discontinuations (all cause, lack of efficacy, adverse event, gastrointestinal adverse event), endoscopically detected ulcers, gastrointestinal or cardio-renal events, and major changes in haematological parameters. The main comparisons were celecoxib (all doses) versus placebo, paracetamol (acetaminophen) 4,000 mg daily, rofecoxib 25 mg daily, or nonsteroidal anti-inflammatory drugs (NSAIDs) (naproxen, diclofenac, ibuprofen, and loxoprofen). For NSAIDs, celecoxib was compared both at all doses and at licensed doses (200 to 400 mg daily). Thirty-one trials included 39,605 randomised patients. Most patients had osteoarthritis and were women of average age 60 years or above. Most trials lasted 12 weeks or more. Doses of celecoxib were 50 to 800 mg\/day. Compared with placebo, celecoxib had fewer discontinuations for any cause or for lack of efficacy, fewer serious adverse events, and less nausea. It had more patients with dyspepsia, diarrhoea, oedema, more adverse events that were gastrointestinal or treatment related, and more patients experiencing an adverse event. There were no differences for hypertension, gastrointestinal tolerability, or discontinuations for adverse events. Compared with paracetamol, celecoxib had fewer discontinuations for any cause, for lack of efficacy, or diarrhoea, but no other differences. Compared with rofecoxib, celecoxib had fewer patients with abdominal pain and oedema, but no other differences. Compared with NSAIDs, celecoxib had fewer symptomatic ulcers and bleeds, endoscopically detected ulcers, and discontinuations for adverse events or gastrointestinal adverse events. Fewer patients had any, or a gastrointestinal, or a treatment-related adverse event, or vomiting, abdominal pain, dyspepsia, or reduced haemoglobin or haematocrit. Discontinuations for lack of efficacy were higher. No differences were found for all-cause discontinuations, serious adverse events, hypertension, diarrhoea, nausea, oedema, myocardial infarction, cardiac failure, or raised creatinine. Company clinical trial reports present much more information than published papers. Adverse event information is clearly presented in company clinical trial reports, which are an ideal source of information for systematic review and meta-analysis.<\/jats:p>","DOI":"10.1186\/ar1704","type":"journal-article","created":{"date-parts":[[2005,3,25]],"date-time":"2005-03-25T02:16:08Z","timestamp":1111716968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":183,"title":["Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports"],"prefix":"10.1186","volume":"7","author":[{"given":"R Andrew","family":"Moore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Derry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey T","family":"Makinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry J","family":"McQuay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,3,24]]},"reference":[{"key":"1584_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1093\/rheumatology\/36.1.74","volume":"36","author":"J Fear","year":"1997","unstructured":"Fear J, Hillman M, Chamberlain MA, Tennant A: Prevalence of hip problems in the population aged 55 years and over: access to specialist care and future demand for hip arthroplasty. Br J Rheumatol. 1997, 36: 74-76. 10.1093\/rheumatology\/36.1.74.","journal-title":"Br J Rheumatol"},{"key":"1584_CR2","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/S0140-6736(99)03057-3","volume":"354","author":"AM Elliott","year":"1999","unstructured":"Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA: The epidemiology of chronic pain in the community. Lancet. 1999, 354: 1248-1252. 10.1016\/S0140-6736(99)03057-3.","journal-title":"Lancet"},{"key":"1584_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1185\/030079902125000345","volume":"18","author":"B Crichton","year":"2002","unstructured":"Crichton B, Green M: GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the pain in osteoarthritis. Curr Med Res Opin. 2002, 18: 92-96. 10.1185\/030079902125000345.","journal-title":"Curr Med Res Opin"},{"key":"1584_CR4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/archinte.164.12.1299","volume":"164","author":"L Fraenkel","year":"2004","unstructured":"Fraenkel L, Bogardus ST, Concato J, Wittink DR: Treatment options in knee osteoarthritis. The patient's perspective. Arch Intrn Med. 2004, 164: 1299-1304. 10.1001\/archinte.164.12.1299.","journal-title":"Arch Intrn Med"},{"key":"1584_CR5","first-page":"708","volume":"22","author":"D Scholes","year":"1995","unstructured":"Scholes D, Stergachis A, Penna PM, Normand EH, Hansten PD: Nonsteroidal anti-inflammatory drug discontinuation in patients with osteoarthritis. J Rheumatol. 1995, 22: 708-712.","journal-title":"J Rheumatol"},{"key":"1584_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3111\/199902045055","volume":"2","author":"RA Moore","year":"1999","unstructured":"Moore RA, Phillips CJ: Cost of NSAID adverse effects to the NHS. J Med Econ. 1999, 2: 45-55.","journal-title":"J Med Econ"},{"key":"1584_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0304-3959(99)00267-5","volume":"85","author":"MR Tramer","year":"2000","unstructured":"Tramer MR, Moore RA, Reynolds DJ, McQuay HJ: Quantitative estimation of rare adverse effects which follow a biological progression \u2013 a new model applied to chronic NSAID use. Pain. 2000, 85: 169-182. 10.1016\/S0304-3959(99)00267-5.","journal-title":"Pain"},{"key":"1584_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1046\/j.1365-2125.1997.00631.x","volume":"44","author":"D Henry","year":"1997","unstructured":"Henry D, Page J, Whyte I, Nanra R, Hall C: Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. Br J Clin Pharmacol. 1997, 44: 85-90. 10.1046\/j.1365-2125.1997.00631.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1584_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/oxfordjournals.aje.a010234","volume":"151","author":"MR Griffin","year":"2000","unstructured":"Griffin MR, Yared A, Ray WA: Nonsteroidal antiinflamatory drugs and acute renal failure in elderly persons. Am J Epidemiol. 2000, 151: 488-496.","journal-title":"Am J Epidemiol"},{"key":"1584_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1001\/archinte.160.6.777","volume":"160","author":"J Page","year":"2000","unstructured":"Page J, Henry D: Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000, 160: 777-784. 10.1001\/archinte.160.6.777.","journal-title":"Arch Intern Med"},{"key":"1584_CR11","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/00001648-200303000-00020","volume":"14","author":"A Garcia-Rodriguez","year":"2003","unstructured":"Garcia-Rodriguez A, Hernandez-Diaz S: Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003, 14: 240-246. 10.1097\/00001648-200303000-00020.","journal-title":"Epidemiology"},{"key":"1584_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016\/0197-2456(95)00134-4.","journal-title":"Control Clin Trials"},{"key":"1584_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0304-3959(00)00234-7","volume":"86","author":"LA Smith","year":"2000","unstructured":"Smith LA, Oldman AD, McQuay HJ, Moore RA: Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain. 2000, 86: 119-132. 10.1016\/S0304-3959(00)00234-7.","journal-title":"Pain"},{"key":"1584_CR14","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled: the QUOROM statement. Lancet. 1999, 354: 1896-1900. 10.1016\/S0140-6736(99)04149-5.","journal-title":"Lancet"},{"key":"1584_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","volume":"78","author":"RA Moore","year":"1998","unstructured":"Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ: Size is everything \u2013 large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998, 78: 209-216. 10.1016\/S0304-3959(98)00140-7.","journal-title":"Pain"},{"key":"1584_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0002-9149(03)00659-3","volume":"92","author":"WB White","year":"2003","unstructured":"White WB, Faich G, Borer JS, Makuch RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol. 2003, 92: 411-418. 10.1016\/S0002-9149(03)00659-3.","journal-title":"Am J Cardiol"},{"key":"1584_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0304-3959(99)00302-4","volume":"85","author":"DJ Gavaghan","year":"2000","unstructured":"Gavaghan DJ, Moore RA, McQuay HJ: An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain. 2000, 85: 415-424. 10.1016\/S0304-3959(99)00302-4.","journal-title":"Pain"},{"key":"1584_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","volume":"53","author":"JA Sterne","year":"2000","unstructured":"Sterne JA, Gavaghan D, Egger M: Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000, 53: 1119-1129. 10.1016\/S0895-4356(00)00242-0.","journal-title":"J Clin Epidemiol"},{"key":"1584_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0895-4356(99)00204-8","volume":"53","author":"J-L Tang","year":"2000","unstructured":"Tang J-L, Liu JLY: Misleading funnel plot for detection of bias in meta-analysis. J Clin Epidemiol. 2000, 53: 477-484. 10.1016\/S0895-4356(99)00204-8.","journal-title":"J Clin Epidemiol"},{"key":"1584_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","volume":"107","author":"KA L'Abbe","year":"1987","unstructured":"L'Abbe KA, Detsky AS, O'Rourke K: Meta-analysis in clinical research. Ann Intern Med. 1987, 107: 224-233.","journal-title":"Ann Intern Med"},{"key":"1584_CR21","first-page":"50","volume-title":"Statistics with Confidence \u2013 Confidence Intervals and Statistical Guidelines","author":"JA Morris","year":"1995","unstructured":"Morris JA, Gardner MJ: Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. Statistics with Confidence \u2013 Confidence Intervals and Statistical Guidelines. Edited by: Gardner MJ, Altman DG. 1995, London: British Medical Journal, 50-63."},{"key":"1584_CR22","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","volume":"310","author":"RJ Cook","year":"1995","unstructured":"Cook RJ, Sackett DL: The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995, 310: 452-454.","journal-title":"BMJ"},{"key":"1584_CR23","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","volume":"282","author":"MJ Langman","year":"1999","unstructured":"Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999, 282: 1929-1933. 10.1001\/jama.282.20.1929.","journal-title":"JAMA"},{"key":"1584_CR24","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","volume":"95","author":"JL Goldstein","year":"2000","unstructured":"Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS: Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 2000, 95: 1681-1690. 10.1111\/j.1572-0241.2000.02194.x.","journal-title":"Am J Gastroenterol"},{"key":"1584_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00045391-200007030-00004","volume":"7","author":"A Whelton","year":"2000","unstructured":"Whelton A, Maurath CJ, Verburg KM, Geis GS: Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. Am J Ther. 2000, 7: 159-175.","journal-title":"Am J Ther"},{"key":"1584_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0002-9149(01)02201-9","volume":"89","author":"AS Reicin","year":"2002","unstructured":"Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q: Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol. 2002, 89: 204-209. 10.1016\/S0002-9149(01)02201-9.","journal-title":"Am J Cardiol"},{"key":"1584_CR27","doi-asserted-by":"crossref","unstructured":"Garner S, Fidan D, Frankish R, Judd M, Towheed T, Wells G, Tugwell P: Rofecoxib for rheumatoid arthritis (Cochrane Review). The Cochrane Library. 2004, Chichester, UK: John Wiley & Sons, 3","DOI":"10.1002\/14651858.CD003685.pub2"},{"key":"1584_CR28","doi-asserted-by":"crossref","unstructured":"Garner S, Fidan D, Frankish R, Judd M, Shea B, Towheed T, Wells G, Tugwell P: Celecoxib for rheumatoid arthritis (Cochrane Review). The Cochrane Library. 2004, Chichester, UK: John Wiley & Sons, 3","DOI":"10.1002\/14651858.CD003685.pub2"},{"key":"1584_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.325.7365.619","volume":"325","author":"JJ Deeks","year":"2002","unstructured":"Deeks JJ, Smith LA, Bradley MD: Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002, 325: 1-8. 10.1136\/bmj.325.7365.619.","journal-title":"BMJ"},{"key":"1584_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.pain.2004.07.004","volume":"111","author":"JE Edwards","year":"2004","unstructured":"Edwards JE, McQuay HJ, Moore RA: Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Pain. 2004, 111: 286-296. 10.1016\/j.pain.2004.07.004.","journal-title":"Pain"},{"key":"1584_CR31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1742-1241.2001.tb11025.x","volume":"55","author":"M Clarke","year":"2001","unstructured":"Clarke M, Halsey J: DICE2: a further investigation of the effects of chance in life, death and subgroup analyses. Int J Clin Pract. 2001, 55: 240-242.","journal-title":"Int J Clin Pract"},{"key":"1584_CR32","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK: Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000, 356: 1255-1259. 10.1016\/S0140-6736(00)02799-9.","journal-title":"Lancet"},{"key":"1584_CR33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0885-3924(99)00093-7","volume":"18","author":"JE Edwards","year":"1999","unstructured":"Edwards JE, McQuay HJ, Moore RA, Collins SL: Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage. 1999, 18: 427-437. 10.1016\/S0885-3924(99)00093-7.","journal-title":"J Pain Symptom Manage"},{"key":"1584_CR34","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1136\/ard.2003.017236","volume":"63","author":"C Miceli-Richard","year":"2004","unstructured":"Miceli-Richard C, Le Bars M, Schmidely N, Dougados M: Paracetamol in osteoarthritis of the knee. Ann Rheum Dis. 2004, 63: 923-930. 10.1136\/ard.2003.017236.","journal-title":"Ann Rheum Dis"},{"key":"1584_CR35","first-page":"372","volume-title":"Ann Rheum Dis","author":"J Goldstein","year":"2004","unstructured":"Goldstein J, Bjarnason I, Moore A, Spalding W, Cawkwell G: Comparison of hemoglobin and hematocrit changes associated with valdecoxib and nonspecific NSAIDs: pooled analysis of randomized trials in patients with OA or RA. Ann Rheum Dis. 2004, 372-"},{"key":"1584_CR36","first-page":"A1","volume-title":"Gastroenterology","author":"J Goldstein","year":"2004","unstructured":"Goldstein J, Bjarnason I, Spalding W, Cawkwell G, Moore A: Long-term NSAIDs but not COX-2 specific inhibitors are associated with anemia [abstract]. Gastroenterology. 2004, A1-"},{"key":"1584_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1053\/j.gastro.2004.05.001","volume":"127","author":"L Laine","year":"2004","unstructured":"Laine L, Maller ES, Yu C, Quan H, Simon T: Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology. 2004, 127: 395-402. 10.1053\/j.gastro.2004.05.001.","journal-title":"Gastroenterology"},{"key":"1584_CR38","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000, 284: 1247-1255. 10.1001\/jama.284.10.1247.","journal-title":"JAMA"},{"key":"1584_CR39","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000, 343: 1520-1528. 10.1056\/NEJM200011233432103.","journal-title":"N Engl J Med"},{"key":"1584_CR40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","volume":"325","author":"M Mamdani","year":"2002","unstructured":"Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin PC, Laupacis A: Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 2002, 325: 624-629. 10.1136\/bmj.325.7365.624.","journal-title":"BMJ"},{"key":"1584_CR41","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1136\/gut.52.9.1265","volume":"52","author":"TM MacDonald","year":"2003","unstructured":"MacDonald TM, Morant SV, Goldstein JL, Burke TA, Pettitt D: Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut. 2003, 52: 1265-1270. 10.1136\/gut.52.9.1265.","journal-title":"Gut"},{"key":"1584_CR42","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1365-2036.2004.01913.x","volume":"19","author":"B N\u00f8rg\u00e5rd","year":"2004","unstructured":"N\u00f8rg\u00e5rd B, Pedersen L, Johnsen SP, Tarone RE, McLaughlin JK, Friis S, Sorensen HT: COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther. 2004, 19: 817-825. 10.1111\/j.1365-2036.2004.01913.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"1584_CR43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1185\/030079903125001910","volume":"19","author":"LR Arboleya","year":"2003","unstructured":"Arboleya LR, de la Figuera E, Soledad Garcia M, Aragon B, VICOXX Study Group: Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. Curr Med Res Opin. 2003, 19: 288-297. 10.1185\/030079903125001910.","journal-title":"Curr Med Res Opin"},{"key":"1584_CR44","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","volume":"43","author":"C Hawkey","year":"2000","unstructured":"Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E: Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum. 2000, 43: 370-377. 10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D.","journal-title":"Arthritis Rheum"},{"key":"1584_CR45","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1136\/gut.52.6.820","volume":"52","author":"CJ Hawkey","year":"2003","unstructured":"Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J, Rofecoxib Rheumatoid Arthritis Endoscopy Study Group: Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut. 2003, 52: 820-826. 10.1136\/gut.52.6.820.","journal-title":"Gut"},{"key":"1584_CR46","first-page":"38","volume":"16","author":"C Harley","year":"2003","unstructured":"Harley C, Wagner S: Persistence with COX-2 inhibitors in managed care: an analysis of claims data. Manag Care Interface. 2003, 16: 38-45.","journal-title":"Manag Care Interface"},{"key":"1584_CR47","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0016-5085(03)00900-4","volume":"125","author":"L Laine","year":"2003","unstructured":"Laine L, Wogen J, Yu H: Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology. 2003, 125: 389-395. 10.1016\/S0016-5085(03)00900-4.","journal-title":"Gastroenterology"},{"key":"1584_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/ard.60.4.349","volume":"60","author":"PC G\u00f8tzsche","year":"2001","unstructured":"G\u00f8tzsche PC: Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. Ann Rheum Dis. 2001, 60: 349-352. 10.1136\/ard.59.6.407.","journal-title":"Ann Rheum Dis"},{"key":"1584_CR49","volume-title":"DPhil Thesis","author":"J Barden","year":"2004","unstructured":"Barden J: Meta-analysis to investigate methodological issues in clinical trials using pain as an exemplar. DPhil Thesis. 2004, Oxford University, Nuffield Department of Anesthetics"},{"key":"1584_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1472-6904-1-3","volume":"1","author":"YK Loke","year":"2001","unstructured":"Loke YK, Derry S: Reporting of adverse drug reactions in randomised controlled trials \u2013 a systematic survey. BMC Clin Pharmacol. 2001, 1: 3-10.1186\/1472-6904-1-3.","journal-title":"BMC Clin Pharmacol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1704.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar1704\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1704.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:41:28Z","timestamp":1728369688000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar1704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,24]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,3]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1186\/ar1704","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,24]]},"assertion":[{"value":"24 November 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2005","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2005","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2005","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R644"}}